Trial
NCT02719132
Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice
Phase IVWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
AstraZeneca
Collaborators
—
Condition
Diabetes Mellitus Type 2
Intervention
Dapagliflozin
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-05-20